ScreenerHero

ALLO Allogene Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · allogene.com
1.430USD-2.05%Mkt Cap: 494.05M $P/E: —

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipe…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap494.05M USD
Enterprise Value250.82M USD
Revenue (TTM)4.64M USD
Gross Profit-117.88M USD
Net Income (TTM)-190.89M USD
Revenue/Share0.02 USD
Last Price1.430 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees150
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.24
PEG—
EV/EBITDA-1.49
EV/Revenue54.06
P/S108.71
P/B1.16
EPS (TTM)-0.66
EPS (Forward)-0.65
52W Range
1.04011% of range4.460
52W High4.460 USD
52W Low1.040 USD
Profitability
Gross Margin0.00%
Oper. Margin-1011.21%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-65.25%
ROA-45.90%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-149.25M USD
CapEx (TTM)386.00K USD
FCF Margin-1367.71%
FCF Yield-12.85%
Net Debt-253.59M USD
Net Debt/EBITDA1.50
Balance Sheet
Debt/Equity0.28
Current Ratio10.72
Quick Ratio10.55
Book Value/Sh1.26 USD
Cash/Share0.96 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.000 USD
Upside (mean)+529.4%
Target Range4.000 USD – 14.00 USD
4.000+529.4% to mean14.00
# Analysts9
Ownership
Shares Out.345.49M
Float281.13M
Insiders11.03%
Institutions82.60%
Short Interest
Short Ratio11.7d
Short % Float19.09%
Short % Out.17.25%
Shares Short59.60M
Short (prev mo.)58.95M
Technical
SMA 501.868 (-23.4%)
SMA 2001.993 (-28.3%)
Beta0.56
S&P 52W Chg16.45%
Avg Vol (30d)5.51M
Avg Vol (10d)5.38M
Technical Indicators
RSI (14)20.7
MACD-0.1161
MACD Signal-0.0979
MACD Hist.-0.0182
BB Upper1.881 USD
BB Middle1.649 USD
BB Lower1.418 USD
BB Width28.05%
ATR (14)0.0847 USD
Vol Ratio (20d)0.66x